Supernus Pharmaceuticals, Inc.SUPNNASDAQ

Revenue (LTM)

$719M

+8.6% YoY

Net Income (LTM)

$-39M

-152.2% YoY

Free Cash Flow

$46M

Revenue CAGR (5Y)

+6.7%

—Marginsstable

FCF$0.0B

Now unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	580	667↑15.1%	608↓8.9%	662↑8.9%	719↑8.6%
Gross Profit	505	580↑14.9%	524↓9.7%	584↑11.5%	644↑10.4%
Operating Income	86	46↓46.4%	-5↓111.4%	82↑1649.9%	-37↓145.1%
Net Income	53	61↑13.6%	1↓97.8%	74↑5512.8%	-39↓152.2%
EBITDA	129	153↑18.7%	90↓41.3%	178↑98.0%	41↓77.0%
EPS Diluted	0.98	1.04↑6.1%	0.02↓97.7%	1.32↑5469.6%	-0.68↓151.5%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	203	93↓54.2%	75↓19.4%	69↓7.6%	128,448↑185167.8%
Total Current Assets	602	734↑22.0%	493↓32.8%	686↑39.1%	644,182↑93794.5%
Total Assets	1,689	1,703↑0.8%	1,278↓25.0%	1,368↑7.1%	1,452,648↑106082.1%
Total Current Liabilities	315	688↑118.1%	290↓57.8%	292↑0.8%	338,171↑115554.7%
Total Liabilities	873	816↓6.5%	356↓56.4%	332↓6.7%	390,934↑117530.7%
Total Equity	816	886↑8.6%	922↑4.0%	1,036↑12.4%	1,061,714↑102408.5%
Total Debt	427	445↑4.2%	42↓90.7%	34↓17.5%	30,365↑88502.6%
Net Debt	224	352↑57.3%	-34↓109.5%	-35↓4.6%	-98,083↓279657.6%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	127	117↓8.1%	111↓4.9%	172↑54.8%	47↓72.5%
Capital Expenditure	-2	-0↑79.9%	-1↓33.7%	-1↓31.6%	-1↓84.6%
Free Cash Flow	125	116↓6.9%	111↓5.1%	171↑54.9%	46↓73.1%
Stock-Based Comp	18	18↓1.9%	27↑52.3%	28↑3.7%	33↑19.1%
Net Change in Cash	-85	-110↓29.5%	-18↑83.6%	-6↑68.3%	61↑1158.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance